Estera Phase I
Estera Phase I, licence 80048540: inactive licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Licence holder
- NuSkin Canada Inc.
- NPN or DIN-HM
- 80048540
- Status
- Inactive licence
- Licence date
- 24 February 2014
- Revision date
- 12 November 2019
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
- Conditions légales
Vitex agnus-castus L.: L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Borago officinalis L.: Les préparations de cette plante sont autorisées s'il peut être démontré qu'elles ne dépassent pas 1 ppb d'alcaloïdes pyrrolizidiniques.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Linum usitatissimum L.: L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
- Conditions légales
Glycine max. (L.) Merr.: La portion journalière recommandée ne doit pas conduire à une ingestion d'isoflavones supérieure à 1 mg/kg de poids corporel (exprimés comme aglycone du composant principal). L'étiquetage doit comporter un avertissement déconseillant l'usage chez les femmes ayant des antécédents personnels ou familiaux de cancer du sein.
arrêté du 24 juin 2014, annexe I. French orders of 9 May 2006 (nutrients), 24 June 2014 (plants) and 26 September 2016 (other substances), consolidated LEGI collection, retrieved 23 October 2026.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| 3,3'-Methylenebis-1H-indole Source : Brassica oleracea var. italica | 50.0 mg | Not calculated |
| Vitex agnus-castus Source : Fruit Extract : Matériel brut sec Extraction ratio : 7.5:1 Dry plant equivalent : 937.5 mg Potency : 0.2 % Casticin | 125.0 mg | Not calculated |
| Punica granatum Source : Fruit Extraction ratio : 9:1 Dry plant equivalent : 180 mg Potency : 60.0 % Polyphenols | 20.0 mg | Not calculated |
| Vitamine B6 Source : Pyridoxine HCl | 25.0 mg | Not calculated |
| Borago officinalis Source : Graine(s) Potency : 20.0 % GLA | 125.0 mg | Not calculated |
| Oenothera biennis Source : Graine(s) Potency : 9.0 % GLA | 250.0 mg | Not calculated |
| Linum usitatissimum Source : Graine(s) | 37.5 mg | Not calculated |
| Glycine max Source : Fève Potency : 12.8 mg ÉAI Total Isoflavones | 20.0 mg | Not calculated |
| Glycine max Source : Fève Potency : 5.0 mg ÉAI Genistein | Not specified | Not calculated |
Non-medicinal ingredients
Couleur caramel, Glycérine, Gélatine, Cire d'abeille jaune, Huile de fève de soja
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes de sexe féminin | Not specified | 2.0 Capsule | Not specified |
Uses authorised in Canada
Text supplied in English because no French text is available.
Used in herbal medicine to help relieve common PMS symptoms and as a hormone normalizer to help stabilize menstrual irregularities. A source of antioxidants to support good health.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80048540
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
List in the official revision dated (register: Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks).
List recorded in 2019. Photograph the packaging to check whether it has changed.
Has the product changed? Photograph the packaging.